NCT07309120

Nutrition Ameliorates the Muscle Loss of Pre-sarcopenia in Elderly

Completed NA Last updated 8 January 2026

What this trial tests

NA trial testing Participants consume two sachets daily over a 12-week intervention period. in Low Muscle Mass in 60 participants. Completed in 20 June 2023.

Timeline

24 December 2021

Primary endpoint
31 May 2023

20 June 2023

Quick facts

Lead sponsor	Chang Gung Memorial Hospital
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	60
Start date	24 December 2021
Primary completion	31 May 2023
Estimated completion	20 June 2023
Sites	1 location across Taiwan

Drugs / interventions tested

• Participants consume two sachets daily over a 12-week intervention period.

Conditions studied

• Low Muscle Mass — all drugs for Low Muscle Mass →
• Low Muscle Strength — all drugs for Low Muscle Strength →
• Low Physical Function — all drugs for Low Physical Function →

Sponsor

Chang Gung Memorial Hospital

Who can join

Adults 60 to 90, any sex, with Low Muscle Mass or Low Muscle Strength. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study evaluates the effects of a 12-week leucine-enriched protein supplementation in adults aged 60 years and more. Participants will undergo assessments of muscle mass and function, as well as metabolic profiles in blood, urine, and feces before and after the intervention.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. Elevated trimethylamine levels characterize impaired muscle mass response to leucine-enriched protein supplementation in older adults at risk of sarcopenia.
   Tang HY, Lo CJ, Ho HY, Yang CH, et al · · 2026 · PMID 41935035 · DOI 10.1038/s41514-026-00375-9